Diabetes & Obesity Drugs May slow Alcohol Absorption

A new study from the Fralin Biomedical research Institute at Virginia Tech Carilion (VTC) shows how medications for diabetes and obesity might affect how the body processes alcohol. These medications, called GLP-1 receptor agonists-including semaglutide, tirzepatide, and liraglutide (brand names like Ozempic and Wegovy)-help manage metabolic disorders and may also help with alcohol misuse. The research suggests these drugs can slow down how quickly alcohol enters the bloodstream, reducing its effects on the brain.

GLP-1 receptor agonists are known for improving blood sugar control and helping people lose weight by controlling appetite and insulin. But this study looks at their other effects, especially related to alcohol. Researchers published their findings in Scientific Reports. They studied how people with obesity responded to alcohol, comparing those taking GLP-1 agonists to those who weren’t taking any medication.

The study found that people taking GLP-1 agonists absorbed alcohol more slowly. This meant they felt less intoxicated.

Researchers recruited 20 adults with a body mass index (BMI) of 30 or higher. half where taking GLP-1 therapy, and half were not.Before giving participants alcohol (to reach a blood-alcohol level around 0.08 percent), everyone fasted and ate a standard snack. This helped ensure consistent stomach contents, which affects how quickly alcohol is absorbed. Researchers tracked blood pressure, pulse, blood sugar, and breath alcohol levels. They also used questionnaires to measure how intoxicated participants felt.

The study suggests that GLP-1 agonists slow down gastric emptying-how quickly food and liquids leave the stomach. by slowing this process, the drugs reduce how quickly alcohol reaches the small intestine, where it’s absorbed into the bloodstream. This can definitely help prevent a rapid rise in blood alcohol levels. This coudl lower the risk of binge drinking and alcohol abuse, where fast intoxication can lead to addictive behaviors.

People taking GLP-1 agonists reported feeling substantially less drunk than those not on the medication, even though they drank the same amount of alcohol. This suggests the drugs might affect brain reward pathways by changing how alcohol is processed, or possibly through a direct effect on brain chemistry. More research is needed to understand this better.